1e
19
1
49
2
2
18
1b
1d
18
38
80
1d
2 29
1d
25
John Nicholas Lukens, M.D.
78
80
Associate Professor of Radiation Oncology at the Hospital of the University of Pennsylvania
28
74
3
69
Site Chief, Head and Neck Service, University of Pennsylvania
11
Department: Radiation Oncology
4
1
b
1d
46
Contact information
53
4
3
3
3
2
4
b
1f
53
Perelman Center for Advanced Medicine
1f 3400 Civic Center Blvd.
29 2-West
Philadelphia, PA 19104
26
1f 3400 Civic Center Blvd.
29 2-West
Philadelphia, PA 19104
2e
Office: 215-662-6567
30
f
30
13
Education:
21 7 BA 25 ((Distinction in History)) c
29 Yale University, 1999.
21 7 MD c
46 University of Pennsylvania School of Medicine, 2008.
c
3
3
3
3
8d
Permanent link21 7 BA 25 ((Distinction in History)) c
29 Yale University, 1999.
21 7 MD c
46 University of Pennsylvania School of Medicine, 2008.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
32f My clinical expertise is in the treatment of head and neck cancers and gastrointestinal cancers. Additionally, I have specialized training in brachytherapy, which consists of placing radioactive sources within, or directly adjacent to a tumor, as a means of delivering highly targeted radiation. I have experience in head and neck, prostate, and gastrointestinal brachytherapy, as well as intra-operative radiotherapy. I have a particular clinical interest in the re-treatment of patients who have undergone a prior course of radiation, through the integration of highly targeted techniques such as proton therapy and brachytherapy. I believe strongly in the importance of an interdisciplinary approach, and work closely with my surgical and medical oncology colleagues to optimize patient outcomes.71
Description of Research Expertise
1ca My research focuses on the multidisciplinary management of head and neck cancers, in particular novel strategies to understand and mitigate the toxicities associated with head and neck radiotherapy. Additionally, I am interested in identifying subsets of patients with HPV+ cancer who may benefit from treatment de-intensification, and conversely, those with high-risk disease who may benefit from novel targeted therapy and/or immunotherapy.e 29
23
173 Deng J, Murphy BA, Andersen LP, McMenamin E, Lukens JN, Cohn JC, Rajasekaran K, Quinn RJ, Spinelli BA, Lin A.: Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial. Oral Oncol. Sept 2025
186 Ghanian A, DiBona J, Duda L, Xu X, Lukens JN, Pearce T, Ehrhardt M, Rook A, Durham A, Maity A, Flesner B.: Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot study. Vet Oncol. 2(1), Aug 2025.
1e0 Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D: Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer. J Natl Cancer Inst 117(7): 1366-1376, July 2025.
24e Bordeaux J, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bolotin D, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, LeBoeuf N, Lukens JN, Manber S, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha AR, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. : Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. Jan 2025.
1d3 Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D: Association of oropharyngeal cancer recurrence with tumor-intrinsic and immune-mediated sequelae of reduced genomic instability. bioRxiv 4: 2024.10.31.621311, Nov 2024.
138 Hanna GJ, Jabalee J, Lukens JN, Sun L, Rettig EM, Ferrandino R 2nd, Posner MR, Misiukiewicz KJ, Routman DM, Van Abel KM, Del Vecchio Fitz C, Roof SA: Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA in Recurrent, Metastatic HPV-driven Oropharyngeal Cancer f Oral Oncology 3d Oral Oncology 158: 107002, Nov 2024.
103 Pepin A, Kiess A, Lukens JN, Mulugeta P, Taunk NK.: Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy. Pract Radiat Oncol. S1879-8500(24): 00299-6, Nov 2024.
1e7 Su W, Anstadt EJ, Gupta N, Groover M, Forrester V, Wang X, Krausz A, Schoenfeld J, Koyfman S, Vidimos A, Stevenson M, Carucci J, Ruiz ES, Lukens JN: Definitive Radiotherapy is a Viable Treatment for Locally Advanced Basal Cell Carcinoma Otherwise Requiring Radical or Disfiguring Resection. International Journal of Radiation Oncology, Biology, Physics S0360-3016(24): 03408-4, Sep 2024 Notes: epub ahead of print.
10a Patel AM, Haleem A, Maxwell R, Lukens JN, Lin A, Brody RM, Brant JA, Carey RM: Choice of Adjuvant Radiotherapy Facility in Major Salivary Gland Cancer. Laryngoscope 134(8): 3620-3632, Aug 2024.
2c
7
1d
1f
Selected Publications
23e Trifoi MD, Morales KV, Frankel D, Lin SK, Deitermann AM, Haynes D, Lubeck M, Etzkorn JR, Sobanko JF, Giordano CN, Walker JL, Zhang J, Lewis DJ, Higgins HW 2nd, Miura JT, Karakousis GC, Rajasekaran K, Cannady SB, Brody RM, Mitchell TC, Amaravadi RK, Lukens JN, Miller CJ. : Compliance with guidelines and timeliness of sentinel lymph node biopsy for Merkel cell carcinoma treated with Mohs micrographic surgery versus conventional excision at a tertiary academic center. J Am Acad Dermatol. Oct 2025173 Deng J, Murphy BA, Andersen LP, McMenamin E, Lukens JN, Cohn JC, Rajasekaran K, Quinn RJ, Spinelli BA, Lin A.: Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial. Oral Oncol. Sept 2025
186 Ghanian A, DiBona J, Duda L, Xu X, Lukens JN, Pearce T, Ehrhardt M, Rook A, Durham A, Maity A, Flesner B.: Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot study. Vet Oncol. 2(1), Aug 2025.
1e0 Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D: Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer. J Natl Cancer Inst 117(7): 1366-1376, July 2025.
24e Bordeaux J, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bolotin D, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, LeBoeuf N, Lukens JN, Manber S, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha AR, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. : Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. Jan 2025.
1d3 Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D: Association of oropharyngeal cancer recurrence with tumor-intrinsic and immune-mediated sequelae of reduced genomic instability. bioRxiv 4: 2024.10.31.621311, Nov 2024.
138 Hanna GJ, Jabalee J, Lukens JN, Sun L, Rettig EM, Ferrandino R 2nd, Posner MR, Misiukiewicz KJ, Routman DM, Van Abel KM, Del Vecchio Fitz C, Roof SA: Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA in Recurrent, Metastatic HPV-driven Oropharyngeal Cancer f Oral Oncology 3d Oral Oncology 158: 107002, Nov 2024.
103 Pepin A, Kiess A, Lukens JN, Mulugeta P, Taunk NK.: Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy. Pract Radiat Oncol. S1879-8500(24): 00299-6, Nov 2024.
1e7 Su W, Anstadt EJ, Gupta N, Groover M, Forrester V, Wang X, Krausz A, Schoenfeld J, Koyfman S, Vidimos A, Stevenson M, Carucci J, Ruiz ES, Lukens JN: Definitive Radiotherapy is a Viable Treatment for Locally Advanced Basal Cell Carcinoma Otherwise Requiring Radical or Disfiguring Resection. International Journal of Radiation Oncology, Biology, Physics S0360-3016(24): 03408-4, Sep 2024 Notes: epub ahead of print.
10a Patel AM, Haleem A, Maxwell R, Lukens JN, Lin A, Brody RM, Brant JA, Carey RM: Choice of Adjuvant Radiotherapy Facility in Major Salivary Gland Cancer. Laryngoscope 134(8): 3620-3632, Aug 2024.
2c